Avian influenza

Summary

Avian influenza (MONDO:0018695) is a disease and 29 clinical trials. Top therapeutic interventions include oseltamivir. A subtype of influenza — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 41
• Clinical trials: 29

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		826	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Europe	Validated

Signs & symptoms

Clinical features (HPO)

41 HPO clinical features (Orphanet curated; top 41 by frequency):

HPO ID	Term	Frequency
HP:0001945	Fever	Very frequent (80-99%)
HP:0003326	Myalgia	Very frequent (80-99%)
HP:0012378	Fatigue	Very frequent (80-99%)
HP:0012735	Cough	Very frequent (80-99%)
HP:0025439	Pharyngitis	Very frequent (80-99%)
HP:0001873	Thrombocytopenia	Frequent (30-79%)
HP:0001882	Leukopenia	Frequent (30-79%)
HP:0001888	Lymphopenia	Frequent (30-79%)
HP:0002113	Pulmonary infiltrates	Frequent (30-79%)
HP:0002315	Headache	Frequent (30-79%)
HP:0011227	Elevated circulating C-reactive protein concentration	Frequent (30-79%)
HP:0012418	Hypoxemia	Frequent (30-79%)
HP:0025179	Ground-glass opacification on pulmonary HRCT	Frequent (30-79%)
HP:0031246	Nonproductive cough	Frequent (30-79%)
HP:0000509	Conjunctivitis	Occasional (5-29%)
HP:0002013	Vomiting	Occasional (5-29%)
HP:0002014	Diarrhea	Occasional (5-29%)
HP:0002027	Abdominal pain	Occasional (5-29%)
HP:0002090	Pneumonia	Occasional (5-29%)
HP:0002094	Dyspnea	Occasional (5-29%)
HP:0002202	Pleural effusion	Occasional (5-29%)
HP:0002878	Respiratory failure	Occasional (5-29%)
HP:0005268	Spontaneous abortion	Occasional (5-29%)
HP:0025435	Increased circulating lactate dehydrogenase concentration	Occasional (5-29%)
HP:0031245	Productive cough	Occasional (5-29%)
HP:0100749	Chest pain	Occasional (5-29%)
HP:0001287	Meningitis	Very rare (<1-4%)
HP:0001635	Congestive heart failure	Very rare (<1-4%)
HP:0001919	Acute kidney injury	Very rare (<1-4%)
HP:0002098	Respiratory distress	Very rare (<1-4%)
HP:0002107	Pneumothorax	Very rare (<1-4%)
HP:0002383	Infectious encephalitis	Very rare (<1-4%)
HP:0002789	Tachypnea	Very rare (<1-4%)
HP:0002910	Elevated circulating hepatic transaminase concentration	Very rare (<1-4%)
HP:0003073	Hypoalbuminemia	Very rare (<1-4%)
HP:0003201	Rhabdomyolysis	Very rare (<1-4%)
HP:0003236	Elevated circulating creatine kinase concentration	Very rare (<1-4%)
HP:0005521	Disseminated intravascular coagulation	Very rare (<1-4%)
HP:0012115	Hepatitis	Very rare (<1-4%)
HP:0012486	Myelitis	Very rare (<1-4%)
HP:0100806	Sepsis	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	avian influenza
Mondo ID	MONDO:0018695
EFO	EFO:0005222
MeSH	D005585
Orphanet	454836
DOID	DOID:4492
SNOMED CT	55604004
UMLS	C0016627
MedGen	42091
GARD	0021897
Is cancer (heuristic)	no

Disease family

This is a subtype of influenza. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › viral respiratory tract infection › influenza › avian influenza

Related subtypes (1): swine influenza

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Influenza Virus Vaccine	Phase 3
Aluminum Hydroxide	Phase 2
Oseltamivir	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 29.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	11
PHASE1	11
PHASE3	2
Not specified	2
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07275060	PHASE4	ACTIVE_NOT_RECRUITING	Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
NCT07240558	PHASE3	RECRUITING	Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
NCT02612909	PHASE2/PHASE3	COMPLETED	A Safety and Immunogenicity Study of IVACFLU-A/H5N1
NCT02839330	PHASE3	COMPLETED	A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
NCT00298233	PHASE2	COMPLETED	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
NCT00481065	PHASE2	COMPLETED	Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
NCT00561184	PHASE2	COMPLETED	Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine
NCT00895544	PHASE1/PHASE2	COMPLETED	Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
NCT02213354	PHASE2	COMPLETED	H7N9 Mix and Match With MF59 in Healthy Elderly Persons
NCT02229357	PHASE2	COMPLETED	Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine
NCT02921997	PHASE2	COMPLETED	H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
NCT03312231	PHASE2	COMPLETED	Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
NCT03318315	PHASE2	COMPLETED	Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
NCT03589807	PHASE2	COMPLETED	2013/2017 H7N9 Prime-Boost Interval
NCT03682120	PHASE2	COMPLETED	Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
NCT03738241	PHASE2	COMPLETED	2017 A/H7N9 IIV Revaccination
NCT07019883	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
NCT01335347	PHASE1	COMPLETED	Safety Study of an Oral Vaccine to Prevent Avian Influenza
NCT01511419	PHASE1	COMPLETED	Safety Trial of Live Attenuated Influenza (H7N3) Vaccine
NCT01675284	PHASE1	COMPLETED	A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
NCT01698060	PHASE1	COMPLETED	Immunogenicity of ND1.1 by Delivery Directly to the Ileum
NCT01897701	PHASE1	COMPLETED	A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
NCT02251288	PHASE1	COMPLETED	A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
NCT02295813	PHASE1	COMPLETED	Safety and Pharmacokinetics Study of FBF001
NCT02624219	PHASE1	COMPLETED	H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
NCT03014310	PHASE1	COMPLETED	H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
NCT03472976	PHASE1	COMPLETED	H5N1 With or Without Topical Aldara in Healthy Adults
NCT01107262	Not specified	COMPLETED	Avian Influenza Studies In Lebanon
NCT01150552	Not specified	COMPLETED	Studies of Avian Influenza Transmission to Humans in Egypt

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OSELTAMIVIR	4	1